NasdaqGS:GLUEBiotechs
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative
Monte Rosa Therapeutics (GLUE) just posted its FY 2025 third quarter numbers, with revenue of US$12.8 million and a basic EPS loss of US$0.33 off a net income loss of US$27.1 million, setting a clear snapshot of where the business stands today. Over recent periods, the company has seen revenue move from US$60.6 million in Q4 2024 to US$84.9 million in Q1 2025, then to US$23.2 million in Q2 2025 and US$12.8 million in Q3 2025. Over the same timeframe, basic EPS shifted from a profit of US$0.16...